Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination

Cancer Research

Volumn 74, Issue 3, 2014, Pages 808-817

  Hast, Bridgid E ^a   Cloer, Erica W ^a   Goldfarb, Dennis ^c   Li, Heng ^d   Siesser, Priscila F ^a   Yan, Feng ^a   Walter, Vonn ^b   Zheng, Ning ^d   Hayes, D Neil ^b   Major, Michael B ^a,b,c  

^a Department of Cell Biology and Physiology ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Brooks Computer Science Building   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINE, TUMOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; MUTATION; NEOPLASMS; NF-E2-RELATED FACTOR 2; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEOLYSIS; UBIQUITINATION;

EID: 84893876085     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1655     Document Type: Article

References (44)

1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
2. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005;25:162-71.
3. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol 2006;26:2887-900.
4. Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, et al. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res 2013;73: 2199-210.
5. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who's listening? Antioxid Redox Signal 2010;13: 1649-63.
6. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012;22:66-79.
7. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 2010;70:5486-96.
8. Mahaffey CM, Zhang H, Rinna A, Holland W, Mack PC, Forman HJ. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radic Biol Med 2009;46:1650-7.
9. Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kB and underlies its chemo-resistance. Blood 2012; 120:5188-98.
10. Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res 2013;73:6289-98.
11. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34:176-88.
12. Muscarella LA, Parrella P, D'Alessandro V, la Torre A, Barbano R, Fontana A, et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 2011;6:710-9.
13. Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, et al. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 2012;12:66.
14. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013;23:603-17.
15. Safaee M, Clark AJ, Oh MC, Ivan ME, Bloch O, Kaur G, et al. Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients. PLoS ONE 2013;8:e62765.
16. Hakimi AA, Ostrovnaya I, Reva BA, Schultz N, Chen YB, Gonen M, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013;19:3259-67.
17. Meng X, Cai C, Wu J, Cai S, Ye C, Chen H, et al. TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway. Cancer Lett 2013;333:96-102.
18. WuYM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636-47.
19. Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA, et al. Wilms tumor gene on the X chromosome (WTX) inhibits the degradation of NRF2 through competitive binding to KEAP1. J Biol Chem 2012;287:6539-50.
20. Lo SC, Li X, Henzl MT, Beamer LJ, Hannink M. Structure of the Keap1: Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 2006;25:3605-17.
21. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004; 24:8477-86.
22. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004;24:10941-53.
23. Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, Freeman ML. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem Res Toxicol 2008; 21:705-10.
24. Fourquet S, Guerois R, Biard D, Toledano MB. Activation of NRF2 by nitrosative agents andH2O2 involves KEAP1 disulfide formation. J Biol Chem 2010;285:8463-71.
25. Levine AJ. The tumor suppressor genes. Annu Rev Biochem 1993; 62:623-51.
26. Fujibuchi T, Abe Y, Takeuchi T, Imai Y, Kamei Y, Murase R, et al. AIP1/ WDR1 supports mitotic cell rounding. Biochem Biophys Res Commun 2005;327:268-75.
27. Kato A, Kurita S, Hayashi A, Kaji N, Ohashi K, Mizuno K. Critical roles of actin-interacting protein 1 in cytokinesis and chemotactic migration of mammalian cells. Biochem J 2008;414:261-70.
28. Takei Y, Tsujimoto G. Identification of a novel MCM3-associated protein that facilitates MCM3 nuclear localization. J Biol Chem 1998;273:22177-80.
29. Kubota Y, Mimura S, Nishimoto S, Takisawa H, Nojima H. Identification of the yeast MCM3-related protein as a component of Xenopus DNA replication licensing factor. Cell 1995;81:601-9.
30. Young MR, Tye BK. Mcm2 and Mcm3 are constitutive nuclear proteins that exhibit distinct isoforms and bind chromatin during specific cell cycle stages of Saccharomyces cerevisiae. Mol Biol Cell 1997;8: 1587-601.
31. Wagner S, Flood TA, O'Reilly P, Hume K, Sabourin LA. Association of the Ste20-like kinase (SLK) with the microtubule. Role in Rac1-mediated regulation of actin dynamics during cell adhesion and spreading. J Biol Chem 2002;277:37685-92.
32. Wagner S, Storbeck CJ, Roovers K, Chaar ZY, Kolodziej P, McKay M, et al. FAK/src-family dependent activation of the Ste20-like kinase SLK is required for microtubule-dependent focal adhesion turnover and cell migration. PLoS ONE 2008;3:e1868.
33. Sabourin LA, Rudnicki MA. Induction of apoptosis by SLK, a Ste20-related kinase. Oncogene 1999;18:7566-75.
34. Hao W, Takano T, Guillemette J, Papillon J, Ren G, Cybulsky AV. Induction of apoptosis by the Ste20-like kinase SLK, a germinal center kinase that activates apoptosis signal-regulating kinase and p38. J Biol Chem 2006;281:3075-84.
35. Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, et al. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol 2012;32:1506-17.
36. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nature Cell Biol 2010;12:213-23.
37. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 2009;34:663-73.
38. Kaneko T, Huang H, Cao X, Li X, Li C, Voss C, et al. Superbinder SH2 domains act as antagonists of cell signaling. Sci Signal 2012;5:ra68.
39. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 2009;78:477-513.
40. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008;68:1303-9.
41. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011;71:5081-9.
42. Cong ZX, Wang HD, Wang JW, Zhou Y, Pan H, Zhang DD, et al. ERK and PI3K signaling cascades induce Nrf2 activation and regulate cell viability partly through Nrf2 in human glioblastoma cells. Oncol Rep 2013;30:715-22.
43. Kim JE, You DJ, Lee C, Ahn C, Seong JY, Hwang JI. Suppression of NF-kB signaling by KEAP1 regulation of IKKb activity through autophagic degradation and inhibition of phosphorylation. Cell Signal 2010;22:1645-54.
44. McMahon M, Lamont DJ, Beattie KA, Hayes JD. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A 2010;107: 18838-43.